Seroquel XR Related Published Studies
Well-designed clinical trials related to Seroquel XR (Quetiapine)
Annual cost of relapses and relapse-related hospitalizations in adults with
schizophrenia: results from a 12-month, double-blind, comparative study of
lurasidone vs quetiapine extended-release. [2013]
Randomized, placebo-controlled trial of quetiapine XR and divalproex ER
monotherapies in the treatment of the anxious bipolar patient. [2013]
Predicting 1-year risk for relapse in patients who have discontinued or continued
quetiapine after remission from first-episode psychosis. [2013]
Quetiapine versus haloperidol in the treatment of delirium: a double-blind,
randomized, controlled trial. [2013]
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine
fumarate XR in very heavy-drinking alcohol-dependent patients. [2012]
Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. [2012]
A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. [2011.12]
Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. [2011.11]
Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). [2011.11]
A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. [2011.10]
Quetiapine extended release: adjunctive treatment in major depressive disorder. [2011.09.01]
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). [2011.09]
Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. [2011.08.15]
A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. [2011.06.14]
Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. [2011.06]
A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. [2011.04]
A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. [2011.03]
Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. [2011.01]
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. [2011.01]
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. [2011.01]
Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers. [2011]
Augmentative quetiapine in partial/nonresponders with generalized anxiety
disorder: a randomized, placebo-controlled study. [2011]
A randomized, double-blind, parallel-group, fixed-dose, clinical trial of
quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant
schizophrenia or schizoaffective disorder. [2011]
A double-blind, placebo-controlled, randomized pilot study comparing quetiapine
with placebo, associated to naltrexone, in the treatment of alcohol-dependent
patients. [2011]
Quetiapine in the treatment of psychosis in Parkinson's disease. [2010.11]
A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. [2010.11]
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. [2010.11]
Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. [2010.10]
Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. [2010.10]
Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. [2010.09.28]
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. [2010.08.19]
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial. [2010.08.04]
Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. [2010.07]
Quetiapine for primary insomnia: a double blind, randomized controlled trial. [2010.06]
Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: A pilot study. [2010.05.04]
Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. [2010.05]
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. [2010.04]
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. [2010.03.24]
Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. [2010.03]
Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. [2010.02]
A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). [2010.02]
A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). [2010.02]
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. [2010.02]
A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. [2010.01]
Quetiapine XR: current status for the treatment of major depressive disorder. [2010]
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in
major depressive disorder (MDD) in patients with an inadequate response to
ongoing antidepressant treatment: a multicentre, randomized, double-blind,
placebo-controlled study. [2010]
Effectiveness of the extended release formulation of quetiapine as monotherapy
for the treatment of acute bipolar depression. [2010]
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy
effective in generalized anxiety disorder. Data from a randomized, double-blind,
placebo- and active-controlled study. [2010]
A randomized controlled trial of quetiapine versus placebo in the treatment of
delirium. [2010]
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. [2009.10]
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. [2009.08.20]
A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. [2009.08]
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. [2009.07]
Olanzapine compared to quetiapine in adolescents with a first psychotic episode. [2009.07]
Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. [2009.06]
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. [2009.06]
Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. [2009.04]
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. [2009.04]
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. [2009.04]
Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). [2009.04]
Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. [2009.04]
Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. [2009.03]
A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. [2009]
Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies. [2009]
Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. [2009]
Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. [2008.12]
Dosing quetiapine in drug-naive first-episode psychosis: A controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. [2008.11.18]
Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. [2008.11]
Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. [2008.10]
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. [2008.10]
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. [2008.09]
Bioequivalence study of a generic quetiapine in healthy male volunteers. [2008.09]
Quetiapine for the treatment of bipolar mania in older adults. [2008.09]
The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. [2008.08.28]
Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). [2008.08]
Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. [2008.05.30]
A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. [2008.05]
Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. [2008.05]
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. [2008.05]
Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. [2008.04]
Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. [2008.04]
Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. [2008.03]
Modulation of human motor cortex excitability by quetiapine. [2008.03]
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. [2008.02.15]
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. [2008.02]
Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study. [2008.01]
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. [2008.01]
Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. [2008]
[Administration of once-daily extended release quetiapine in schizophrenic disorders] [2007.12]
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?-A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. [2007.12]
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. [2007.11]
Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine. [2007.11]
Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. [2007.11]
Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. [2007.10.01]
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. [2007.10]
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. [2007.09]
Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. [2007.09]
Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. [2007.08]
A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. [2007.08]
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. [2007.07]
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. [2007.07]
|
